CSI Market
Sign In | Register

Regen Biopharma Inc (RGBP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RGBP Annual Cash Flow →
The cash flow figures below highlight longer-term patterns in how Regen Biopharma Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
9 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-0.61
Depreciation & amortization0.00
Amortization of Other Assets0.03
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Increase (Decrease) in Derivative Liabilities-0.18
Income Loss From Continuing Operations Before Interest Expense Interest Income Income Taxes Extraordinary Items Noncontrolling Interests Net-
Net Income Loss-
Stock Issued-
Common Stock Issued To Consultants-
Preferred Stock Issued-
Increase In Inssuance Of Stock Below Fair Value-
Increase Decrease In Bank Overdraft-
Increase Decrease In Due From Former Employee-
Increase Decrease In Recognition Of Other Than Temporary Impairment-
Gain Loss On Sale Of Investment Securities-
Adjustments To Additional Paid In Capital Other-
Securities Accepted As Compensation-
Increase Decrease In Loss On Sale Of Investment Securities-
Common Stock Issued For Expenses-
Preferred Stock Issued As Compensation-
Net Loss-
Common Stock Issued For Compensation0.40
Increase Decrease In Common Stock Issued For Expenses0.02
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable0.08
Increase (Decrease) in Accounts Payable0.02
Increase (Decrease) in Accrued Liabilities0.17
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.00
Other Working Capital-0.09
Other Noncash Income (Expense)0.07
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.24
Discontinued operations0.00
Net Cash flow from Operating Activities-0.29
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.03
Long-term debt - repayments-0.06
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.24
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Stock Issued During Period Value Issued For Cash-
Preferred Stock Issued For Cash-
Increase Decrease In Convertible Notes Payable-
Borrowings From Notes Payable To Related Parties-0.05
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.22
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.29
Total Cash Flow-0.07
4 historic quarters locked

Sign in to unlock the full Regen Biopharma Inc cash flow history.

Sign In Create Free Account

About Regen Biopharma Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 17, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-038576

Figures are derived from filed reports and may be restated. Historical data is subject to revision.